deltatrials
Completed PHASE2 NCT00786006

Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer

Randomized Phase II Trial of FOLFIRI3 vs. FOLFOX in Gemcitabine-refractory Advanced Pancreatic Cancer

Sponsor: Asan Medical Center

Conditions Metastatic Pancreatic Cancer
Interventions FOLFIRI.3 FOLFOX
Updated 6 times since 2017 Last updated: Dec 5, 2011 Started: Mar 31, 2007 Primary completion: Mar 31, 2009 Completion: Sep 30, 2009

This PHASE2 trial investigates Metastatic Pancreatic Cancer and is currently completed. Asan Medical Center leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Asan Medical Center
Data source: Asan Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Seoul, South Korea